381 related articles for article (PubMed ID: 34320249)
21. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
22. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
23. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
Argyropoulou M; Trigoni A; Kaffenberger J; Stergianou D; Damoraki G; Mingiani E; Micha S; Krispinsky A; Meltzanidou P; Kanni T; Lazaridou E; Giamarellos-Bourboulis EJ
Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
[TBL] [Abstract][Full Text] [Related]
24. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II.
Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM
Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324
[TBL] [Abstract][Full Text] [Related]
25. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
Dudink K; Bouwman K; Chen Y; DePrimo SE; Munoz-Elias EJ; Aarts P; Schappin R; Florencia EF; van Heeswijk B; Prens LM; van der Zee HH; Prens EP; van Straalen KR; Horváth B
Br J Dermatol; 2023 Apr; 188(5):601-609. PubMed ID: 36811949
[TBL] [Abstract][Full Text] [Related]
26. Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab.
Stergianou D; Tzanetakou V; Argyropoulou M; Kanni T; Bagos PG; Giamarellos-Bourboulis EJ
Dermatology; 2021; 237(3):372-377. PubMed ID: 33401280
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa.
Tzellos T; van Straalen KR; Kyrgidis A; Alavi A; Goldfarb N; Gulliver W; Jemec GBE; Lowes MA; Marzano AV; Prens EP; Sayed CJ; van der Zee HH; Zouboulis CC
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):395-401. PubMed ID: 36184889
[TBL] [Abstract][Full Text] [Related]
28. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
29. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
31. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
[TBL] [Abstract][Full Text] [Related]
32. Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.
Gupta AK; Studholme C
Skin Therapy Lett; 2016 Jul; 21(4):1-4. PubMed ID: 27388530
[TBL] [Abstract][Full Text] [Related]
33. Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.
Fabbrocini G; Ruina G; Giovanardi G; Dini V; Raone B; Venturini M; Caposiena Caro RD; Veraldi S; Cannavò SP; Merlo G; Bertoldi AM; Fiorentini F; Molinelli E; Atzori L; Bongiorno MR; Lo Re M; Skroza N; Lasagni C; Franchi C; Ardigò M; Di Costanzo L; Stingeni L; Amerio P; Sanna F; Pescitelli L; Broganelli P; De Cupis C; Gualberti G; Saragaglia V; Argenziano G
Dermatology; 2022; 238(3):487-497. PubMed ID: 34474409
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
35. Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
Kimball AB; Ganguli A; Fleischer A
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2254-2256. PubMed ID: 29959796
[TBL] [Abstract][Full Text] [Related]
36. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
[TBL] [Abstract][Full Text] [Related]
37. Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.
Giamarellos-Bourboulis EJ; Sobell J; Ryan C; Wolkenstein PJ; Geng Z; Mulder GD
Wounds; 2017 Nov; 29(11):E98-E102. PubMed ID: 29166256
[TBL] [Abstract][Full Text] [Related]
38. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience.
Chiricozzi A; Giovanardi G; Garcovich S; Malvaso D; Caldarola G; Fossati B; Guerriero C; De Simone C; Peris K
Acta Derm Venereol; 2020 Jun; 100(13):adv00172. PubMed ID: 32421198
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: A Randomized Controlled Trial in a real-world setting.
Aarts P; van Huijstee JC; van der Zee HH; van Doorn MBA; van Straalen KR; Prens EP
J Am Acad Dermatol; 2023 Oct; 89(4):677-684. PubMed ID: 37116615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
